process works lead new means early detection treatment alzheimer kosik argues detailed cell biology implicated research fully explored plowing clinical trials targeting tau leading approach moment targeting tau antibodies hope tau people not mistake amyloid people lot tau antibody trials truly understand engaging correct target kosik says not know amyloid not know tau tau forms geneticist michel goedert group cambridge university u.k. different forms specific different conditions tau exists soluble liquid insoluble forms solid precipitates not know toxic form kosik says furthermore researchers not know antibodies actually access offending molecules right ones identified reasons not knowledge invest hundreds millions dollars